Key result
Third-generation drug-eluting stents showed a trend toward lower intrastent thrombus compared to second-generation stents (8% vs. 18%), while stent strut exposure and high platelet reactivity were independent predictors of thrombus.
Why the study?
The mechanism of very late stent failure after newer generation drug-eluting stent implantation has not been fully explored.
Observational (n=100)
No
Answers are grounded in this paper and cite their sources.
May favor third-generation stents for better healing in ACS; leaves open whether this reduces clinical events.
BACKGROUND: Although the incidence of very late stent failure (VLSF) is reduced with newer generation drug-eluting stent (DES), the mechanism of VLSF has not been fully explored. METHODS AND RESULTS: This study evaluated both local vascular healing using coronary angioscopy and systemic factors determined by platelet reactivity at long-term follow-up after 2nd- and 3rd-generation DES implantation in patients with acute coronary syndrome. Coronary angioscopy was performed to assess neointimal coverage (NIC), yellow color (YC) grade and presence of thrombus. The obtained findings were compared with 2nd- and 3rd-DES. Platelet aggregation was assessed by light transmittance aggregometry. 100 consecutive patients were prospectively enrolled: 2nd- (n=50) and 3rd-DES (n=50). 3rd-DES patients had significantly higher NIC grade and lower YC grade compared with 2nd-DES. The presence of thrombus was tended to be lower with 3rd-DES than with 2nd-DES (8% vs. 18%, P=0.11). Patients with thrombus had significantly higher maximum platelet aggregation and higher prevalence of high on-treatment platelet reactivity (HPR) than those without thrombus. Multivariable analysis showed stent strut exposure and HPR as independent predictors of thrombus. CONCLUSIONS: Newer generation DES contribute to better vascular healing depending on the degree of neointimal coverage. In addition to local factors at the stented lesion, systemic factors such as degree of platelet reactivity might also contribute to VLSF.
No takes yet. Share an insight, caveat, or question.
Yoshitaka Iwanaga (2020) conducted an observational in Acute coronary syndrome (n=100). 3rd-generation drug-eluting stent vs. 2nd-generation drug-eluting stent was evaluated on Presence of intrastent thrombus (p=0.11). Third-generation drug-eluting stents showed a trend toward lower intrastent thrombus compared to second-generation stents (8% vs. 18%), while stent strut exposure and high platelet reactivity were independent predictors of thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: